EZH2 promotes a bi-lineage identity in basal-like breast cancer cells

Oncogene

Volumn 32, Issue 33, 2013, Pages 3886-3895

  Granit, R Z ^a   Gabai, Y ^a   Hadar, T ^a,b   Karamansha, Y ^a   Liberman, L ^a   Waldhorn, I ^a   Gat Viks, I ^c   Regev, A ^c   Maly, B ^b   Darash Yahana, M ^b   Peretz, T ^b   Ben Porath, I ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

basal like; breast cancer; differentiation; EZH2; GATA3; Polycomb

Indexed keywords

TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR GATA 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCOMB REPRESSIVE COMPLEX 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTOME; TRANSPLANTATION, HETEROLOGOUS;

EID: 84882452789     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.390     Document Type: Article

References (44)

1. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009; 23: 2563-2577.
2. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
3. Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 2008; 113: 411-422.
4. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271.
5. Gusterson B. Do 'basal-like' breast cancers really exist? Nat Rev Cancer 2009; 9: 128-134.
6. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.
7. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
8. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010; 7: 403-417.
9. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S et al. Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 2011; 109: 2772-2777.
10. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
11. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
12. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-629.
13. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11611.
14. Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev 2012; 26: 751-755.
15. Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, Cornelissen- Steijger P et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008; 10: R109.
16. Alford SH, Toy K, Merajver SD, Kleer CG. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 2012; 132: 429-37.
17. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
18. Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M et al. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 2009; 28: 843-853.
19. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 2009; 106: 5324-5329.
20. Yu J, Cao Q, Mehra R, Laxman B, Tomlins SA, Creighton CJ et al. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by Polycomb in prostate cancer. Cancer Cell 2007; 12: 419-431.
21. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-9218.
22. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006; 125: 301-313.
23. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
24. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Genes Dev 2003; 17: 1253-1270.
25. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
26. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007; 1: 84-96.
27. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005; 5: 675-688.
28. Bouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 2008; 3: 429-441.
29. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F et al. Slug and sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148: 1015-1028.
30. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 2011; 479: 189-193.
31. Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 2012; 10: 183-197.
32. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674-4682.
33. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011; 8: 149-163.
34. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041-1055.
35. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209.
36. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ et al. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13: 141-152.
37. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S et al. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 2011; 31: 4609-4622.
38. Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X et al. Mutation of GATA3 in human breast tumors. Oncogene 2004; 23: 7669-7678.
39. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression metaanalysis. Cancer Res 2005; 65: 11259-11264.
40. Gusterson BA, Ross DT, Heath VJ, Stein T. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res 2005; 7: 143-148.
41. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011; 19: 86-100.
42. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF- 10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256-268.
43. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L et al. Selfinactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.